We use cookies on this site to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies. OK, I agree | Cookies Policy

You are here

Magazine

6

The role of mucoprotectants in the management of gastrointestinal disorders.

Eutamene, Beaufrand Harkat C, Theodorou V.

“The new mucoprotectants, such as gelatin tannate and xyloglucan, have the ability to protect the intestinal mucosa and to exert anti-diarrheal effects. In the future the ability of these substances to enhance the intestinal barrier may extend their use in the management of a variety of gastro-intestinal diseases associated with ‘leaky gut’.

Read more

Aprotecol® launched in Spain

We are pleased to announce the launch of APROTECOL®, our new product for reducing the symptoms of infant colic, in its first market, Spain. The product is distributed by FERRER. Aprotecol® is a Class IIa CE marked medical device intended for the treatment of meteorism, aerophagy and flatulent colic in infants and children. Aprotecol® has been available as drops for oral administration in Spanish pharmacies from the beginning of September.

Read more

New scientific communication on UTIPRO® PLUS

Following the publication of the experimental study by Fraile B et al. “Xyloglucan, hibiscus and propolis for the prevention of urinary tract infections: results of in vitro studies.” on Future Microbiology 2017; 12: 721-73, the authors presented a new communication at the VII International Congress of Histology and Tissue Engineering. Santiago de Compostela 5-8 Sept 2017. The results confirm the non-pharmacological barrier effect of xyloglucan and its utility in the prevention of urinary tract infections.

Read more

Let's meet in..

2018, Aug 29

FNM 2018

FNM-2018-Amsterdam
Read more

2018, Oct 09

CPHI

Read more

2018, Oct 24

UEG Week 2018

Read more

2018, Nov 26

EuroPLX 68

Read more

2018, Nov 29

PharmaVenue November 2018

Read more